Efalizumab (Raptiva) for plaque psoriasis. EMEA recommends withdrawal of its marketing authorization, FDA issues public health advisory
Raptiva and progressive multifocal leukoencephalopathy : EMEA recommends withdrawal of marketing authorization and FDA recommends monitoring patients.
Natalizumab (Tysabri) for multiple sclerosis: AAN guideline and recommendations
The American Academy of Neurology (AAN) published via the National Guideline Clearinghouse a set of recommendations for the use of the monoclonal antibody Natalizumab (Tysabri) for multiple sclerosis: MAJOR RECOMMENDATIONS Definitions of the strength of the recommendations (A, B, C, U) and classification of the evidence (Class I through Class IV) are provided at the […]